Human assessment of the survival and germination of SNZ1969 spores delivered via gummy candies.

Confectionary products hold promise as unconventional food carriers for probiotic microorganisms. This study explored the delivery of SNZ1969, a spore-forming probiotic, using gummy candies. In this study, we prepared gummy candies containing bacterial spores with a viable count that remained stable during a 24-month shelf-life period, meeting the label claim of at least one billion CFUs per serving (24 g).

Safety and Toxicology of Magnolol and Honokiol.

and bark extracts have been used for thousands of years in Chinese and Japanese traditional medicines and are still widely employed as herbal preparations for their sedative, antioxidant, anti-inflammatory, antibiotic, and antispastic effects. Neolignans, particularly magnolol and honokiol, are the main substances responsible for the beneficial properties of the magnolia bark extract (MBE). The content of magnolol and honokiol in MBE depends on different factors, including the plant species, the area of origin, the part of the plant employed, and the method used to prepare the extract.

[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].

Aim: To study clinical efficacy and antihelicobacter activity of combined treatment of duodenal ulcer (DU) with famotidin (qamatel), metronidasol (trichopol) and jozamycin (walpraphen).

Material And Methods: A total of 96 patients with uncomplicated DU have been treated (mean age 42.5 +/- 1.

[Experience in the use of immunomodulator likopid in ulcer disease].

We studied the effect of immunomodulator likopid on leukocytic immunity and duodenal ulcer (DU) course in 92 DU patients (70 males, 22 females; mean age 32 +/- 1.2 years) having positive tests for Helicobacter pylori. The diameter of ulcer defects in the duodenal bulb ranged from 0.

[Clinical efficacy of combined anti-Helicobacter treatment of patients with duodenal ulcer].

84 patients with duodenal ulcer and positive by Helicobacter pylori (HP) were divided into two groups. Group 1 consisted of 42 patients who received omeprasol, metranidasol and clarithromycin. Group 2 of 42 patients received rovamycin instead of clarythromycin.